The 22nd Planova™ Workshop
Oct 10, 2019
Lisbon, Portugal
Workshops & Seminars
- Home
- Workshops & Seminars
Planova™ Workshops and Local Seminars
The Planova Workshop is an opportunity for Planova users to share experiences and to learn the best practices of virus filtration. Event chairs and speakers at this annual event are key industry leaders in biotherapeutics, and their presentations cover topics such as tips for process optimization, validations, regulatory requirements and scaling up to commercial manufacturing. Event attendees include experts in the fields of regulation, process development, pathogen safety, quality and manufacturing. Since the first Planova Workshop held in 1998 in Oslo, Norway, this annual event has greatly contributed to raising awareness on viral safety as well as effective use of virus filtration in the manufacturing processes of biotherapeutics.
Planova Local Seminars are similar events tailored to the needs of certain local regions, with additions of presentations covering case studies from global and local companies as well as regulatory updates on viral safety specific to the region.
In this Page, you can explore details of the upcoming events as well as download materials available from past events (login required).
Upcoming Events
Below you can find details of the upcoming events, including registration forms once they are available.
Latest Workshops
Below you can find details of the last five Planova Workshops and download the presentation materials (login required). To find information on other previous Planova Workshops, click Archive.
-
-
The 21st Planova™ Workshop
Oct 11, 2018 to Oct 12, 2018
-
The 20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
The 19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
The 18th Planova™ Workshop
Oct 22, 2015 to Oct 23, 2015
Athens -
The 17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C.
Latest Seminars
Below you can find details of the last five Local Seminars and download the presentation materials (login required). To find information on other previous Local Seminars, click Archive.
-
2020 Planova™ US Virtual Symposium
Sep 30, 2020 to Oct 2, 2020
-
Planova™ Seminar 2020, Turkey
Sep 15, 2020
Turkey -
Planova™ Seminar 2019, China
Apr 11, 2019 to Apr 12, 2019
Hangzhou, China -
The 3rd Planova™ Seminar in Moscow
Nov 19, 2018
Moscow, Russia -
The Planova™ Seminar in Beijing
Mar 10, 2017
Beijing, China -
The 2nd Planova™ Workshop India
Feb 9, 2017
Goa
Search Presentations
Here you can search and download (login required) presentation materials from past Planova Workshops, by entering keyword or by using filters for each category.
You need to log in to download the files.
-
Challenges of implementing virus filtration in continuous manufacturing
Daniel Strauss, Ph.D., Principal Scientist Science and Technology
Asahi Kasei Bioprocess America
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Evaluating the Impact on Viral Clearance of Multiple Unplanned Interruptions During Virus Removal Filtration
Kevin K. Okimura, Senior Manager Outsourced Manufacturing
Portola Pharmaceuticals
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Clearing the way for viral clearance
David Cetlin, Founder/C.E.O.
MockV Solutions
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Of future biotechnology options and the central role of nanofiltrarion
Andreas Wieser, D (I FH), Senior Laboratory Associate Global Pathogen Safety
Shire
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Meeting Planova and Selecting BioEX for Our Monoclonal Antibody Manufacturing Process
Yumiko Masuda, Scientist Biologics Technology Research Laboratories Biologics Division
Daiichi Sankyo
Meeting Planova and Selecting BioEX for Our Monoclonal Antibody Manufacturing Process
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Challenges & Strategies for Viral Filtration
Matt (Mingjiang) Luo, Ph.D., Executive Director Downstream Process Development and Haikuan Liu, Ph.D., Associate Director Downstream Process Development
Wuxi Biologics (Shanghai)
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
A Case Study: Evaluation of the Effect of Process Pause and Pressure Variation on Planova 20N Virus Filter
Samuel Vollert, Process Development Scientist I Downstream Process Development
Patheon (Thermo Fisher Scientific)
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Clarification Impurities Impact Viral Filtration of a Therapeutic Antibody
Ryan Zolyomi, Senior Development Associate Isolation & Purification Biological Development
Bayer U.S.
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Visualization of behavior of virus and proteins in Planova membrane filters using advanced microscope system with confocal optics
Takayuki Nishizaka, Ph.D., Professor, Department of Physics
Gakushuin University
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Different apparent Size of Parvoviruses determined by Virus Filtration
Thomas Nowak, Ph.D., Senior Manager Pathogen Safety
CSL Behring
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Establishing a Virus Filter Design Space - Impact of Process Interruption on Parvovirus Retention
Ashlee Smith, Associate Scientist BioTherapeutics Development - API; Discovery, Product Development & Supply
Janssen Research & Development
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Overview of Challenges in Virus Filtration: Principles and Applications
Tomoko Hongo-Hirasaki, Ph.D., Senior Scientist Evaluation and Analysis in Virus Filtration Bioprocess Division
Asahi Kasei Medical
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
A Review of Virus Filter Performance
Horst Ruppach, Ph.D., Director, Viral Clearance and Virology Biologics Testing Solutions
Charles River Laboratories
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Update on European Regulations
Johannes Blümel, Ph.D., Head of Virus Safety Section Department of Virology
Paul-Ehrlich-Institut
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA -
Consistent and Reliable 100% Retrovirus Removal by Planova™ 20N filter: Demonstration of Robust Log Reduction (>6.0) by Co-spiking Study
Dayue Chen, Virology Group Bioprocess Research and Development, Eli Lilly and Company
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Virus Inactivation at Low pH: Impact of Buffers, pH Value, Protein Concentration and Temperature on the Inactivation of Retroviruses
Michael Dieterle, Associate Director Downstream Development, Boehringer Ingelheim GmbH&Co.KG
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Implementation of Quality by Design to Nanofiltration of Plasma Products
Monique Ollivier, Director, Process Development-Downstream & Analytics, Cytheris S.A.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
FULL PLASTICS for a 1000L Disposable Production Line for Generic Antibody Manufacturing
Peter Rogge, Director, DSP Production, Rentschler Biotechnologie GmbH
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
New Concept of Integrity Test for Planova™ BioEX
Shinya Sekine, Manager, Technology Development Department, Asahi Kasei Medical Co., Ltd.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
PDA Technical Report 41: Virus Filtration - History and the Future
Kurt Brorson, Staff Scientist, CDER, FDA
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
The Purity of Virus Spikes: Influences on the Performance of Virus Removal Filters
Joseph Hughes, Chief Scientist of Virology and Vice President for Service Development, WuXi AppTec, Inc.
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Viral Filtration of Enzyme Therapeutics Using Planova™ 15N and Planova™ 20N filters
Mei Huei Jang, Senior Scientist, Purification Process Development, Shire Pharmaceuticals
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Integrity Testing of Planova™ BioEX Virus Removal FiltersBioEX Virus Removal Filters
Shinya Sekine, Manager, Technology Development Department Bioprocess Division, Asahi Kasei Medical Co., Ltd.
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Filtration Robustness of Planova™ BioEX Virus-Removal Filter
Tomoko Hongo-Hirasaki, Manager, Technology Development Department, Bioprocess Division, Asahi Kasei Medical Co., Ltd.
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Evaluation of lgG Throughput in Selected Commercial Virus Filters
Joseph Bertolini, R&D Manager, CSL Biotherapies
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Development of Nanofiltered High Purity Fibrinogen
Salvador Grancha, Research and Development Area, Instituto Grifols S.A.
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Implementation of Nanofiltration in the Production Process of Gonadotropins
José Groisman, Director, R&D, Massone S.A.
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Plasma Derivatives and Virus Safety: Relevant Regulations and Guidelines - An Industry Perspective -
Herbert Dichtelmüller, ViruSafe-Consult
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Planova™ Filters - Virus Removal from Biotherapeutic Products -
Ravinder Dabas, Manager, Asahi Kasei India Private Limited
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Validation of Virus Filtration Steps - Practical Aspects for Optimization of the Study Design Leading to Optimal Results -
Olaf Stamm, Senior Specialist, Biopharmaceutical Services, Charles River
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Preparation of Plasma Meeting Requirements for Contract or Domestic Fractionation
Thierry Burnouf, Director, Human Protein Process Sciences
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Plasma Protein Therapy: Current Scene in India and SAARC Region
Ranjeet S. Ajmani, Chief Executive Officer, PlasmaGen BioSciences Pvt. Ltd
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Filtration Study of Planova™ BioEX in the Plasma-derived IvIG Manufacturing Process
Shao Yujuan, R&D Project Leader, Research and Development, Shandong Taibang Biological Product
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Plasma Fractionation - Current Technologies and New Trends -
Sami Chtourou, Senior Vice President, Innovation and Scientific Affairs, LFB Biotechnologies
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Biotherapeutics and Virus Safety: Relevant Regulations and Guidelines
Herbert Dichtelmüller, ViruSafe-Consult
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Application of Planova™ Virus Filters in MAb Purification Processes - Impact on Virus Safety and Process Performance -
Franz Nothelfer, Associate Director, Purification Development, Boehringer Ingelheim Pharma GmbH & Co. KG
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Improvement of MAb Production Cost
Sami Chtourou, Senior Vice President, Innovation and Scientific Affairs, LFB Biotechnologies
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Ensuring Viral Safety in Recombinant Biotherapeutics
Sudip Kumar Majumder, Principal Scientist & Head, Downstream Process Development, Intas Biopharmaceuticals Limited
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Investigations of PCV Removal by Planova™ 15N Filters and Planova™ Filters with Pore Size Smaller than 15 nm
Natascha Hodosi, GLP Study Director, ViruSure
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Asahi Gold Particle Test System Development and Implementation Case Study
Kimo Sanderson, Vice President, Client Services, Asahi Kasei Bioprocess
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Use of Porcine Circovirus as a Challenge for Filtration and Other Virus Risk Mitigation Steps
Kathryn Martin Remington, Principal Scientist, Clearance Services, BioReliance
17th Planova™ Workshop
Dec 12, 2014 to Dec 13, 2014
Washington, D.C. -
Virus Filtration and Biotechnology Processes
Thomas Kreil, Associate Professor of Virology at the Medical University of Vienna and Senior Director, Global Pathogen Safety, Baxter BioScience
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Perspective of Plasma-Derived Products in China
LIU Wenfang, Professor, Institute of Blood Transfusion, Chinese Academy of Medical Sciences/ Peking Union Medical College
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Pathogen Safety of Biological Medicinal Products
Thomas R.KREIL, Associate Professor of Virology, Senior Director Global Pathogen Safety, BaxterBioScience
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
State of the Art Approaches to Ensure Pathogens Safety of Plasma-Derived Products -an Industry Perspective
Thierry BURNOUF, Director, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taiwan
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Planova™ Filters: Virus Removal from Bio-therapeutic Products
LIU Zhanjie, Deputy Manager of Shanghai Representative Office, Bioprocess Division, Asahi Kasei China Co., Ltd., China
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Validation of Virus Filtration Steps
Joseph V. HUGHES, Chief Scientist, Virology, Vice President- Technical Development, WuXi AppTec Inc.
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Blood Products Safety and Regulation in China
HOU Jifeng, Head of Blood Products Division, National Institutes for Food and Drug Control
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
State of the Art of the IVIG Manufacturing
Sami CHTOUROU, Executive Vice President, Innovation & Scientific Affairs, LFB Biotechnologies
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Virus Safety in Blood Plasma-Derived Products-Planova™ Virus Filtration
XU Tan, Project Manager, Research and Development Division, Chengdu Rongsheng Pharmaceuticals Co., Ltd.
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Nanofiltration in IVIG Chromatography Manufacturing Process
MA Shan, Head of Research and Development Division, Joint Venture, Shandong Taibang Biological Products Co., Ltd.
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Current Situation of Viral Clearance for Biological Products in China
FU Rui, Vice Senior Investigator, Division of Laboratory Animal Monitoring, National Institutes for Food and Drug Control
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
State of the Art Manufacturing of Biotechnological Products
Albrecht GROENER, Head Pathogen Safety, CSL Behring
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Asahi Kasei Medical Product Development Concept
MIYABAYASHI Tomoyuki, General Manager, Technical Marketing Department, Asahi Kasei Medical Co., Ltd.
1st Planova™ Workshop in China
Jan 15, 2015
Hainan Island -
Regulatory Update and the Recent Situation in Pathogen Safety
Johannes BLÜMEL, Head of Virus Safety Section, Virology, Paul-Ehrlich-Institut
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Optimization of Virus Removal Filtration Processes: Design of Process Parameters and Virus Validation Studies
Tomoko HONGO-HIRASAKI, Manager, Technology Development, Bioprocess Division, Asahi Kasei Medical
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Virus filtration studies and manufacturing processes: does equivalence need a fresh look?
Andreas WIESER, Senior Laboratory Associate, Global Pathogen Safety, Baxalta
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Robustness of 15 or 20 nm filtration in manufacturing processes of plasma derived medicinal products
Anky KOENDERMAN, Staff member, R&D unit, Sanquin Plasma Products bv
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Defining the Design Spaces for Robust Viral Clearance in Planova™ 20N and BioEX Filter Processes
Daniel STRAUSS, Senior Scientist, Science and Technology, Asahi Kasei Bioprocess America
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Use of MF-SL and Planova™ 20N in the Factor V manufacturing process in Kedrion
Silvia NANNIZZI, Scientist, Industrial Development and Research, Kedrion Spa
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Development of an Improved Downstream Process for Tissue Plasminogen Activator: Implementing QyuSpeed D and Planova™ BioEX
Franz NOTHELFER, Associate Director Protein Science, Biopharmaceuticals, Process Development, Boehringer Ingelheim Pharma GmbH & Co. KG
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Optimization of the Nanofiltration Step within the Manufacturing Process of the Coagulation Factor IX
Eckhard FLECHSIG, Senior Director Pathogen Safety, Global Research, Biotest AG
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Virus Filtration Scalability: Demonstration of Virus Removal Consistency from Small Scale to Manufacturing Scale
Brian BUESING, Research Associate, Science and Technology, Asahi Kasei Bioprocess America, Inc.
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Planova™ Filter in the Production Process of a Gene Therapy Product
Leila DIAS, Scientist DSP, Process Development, uniQure N.V.
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Nanofiltration on Culture Media to Secure Cell and Viral Banks
Landry BERTAUX, Cell and viral culture Scientist, Bioprocess R&D, Sanofi Pasteur
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Approach for Phage Risk Mitigation Using Virus Filter
Simon HAIDINGER, Head of Upstream Development I, Biopharmaceuticals Process Science Austria, Boehringer Ingelheim RCV GmbH & Co KG
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Development of a 20 nm Nanofiltration Step for High Purity Fibrinogen Manufacturing Process
Salvador GRANCHA, Vice-president Research & Development, R&D, Bioscience Industrial Group, Grifols
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Highly Effective and Robust Virus Filtration Design for Early Phase and Commercial Processes
Nathan J ROTH, Director/Head Global Pathogen Safety, R&D, CSL Behring
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Determination of Viral Clearance Design Spaces on Planova™ 20N and BioEX filters - Low Pressure Limits
Josh Goldstein, Senior Scientist, API-LM, Pharmaceutical Development and Manufacturing Sciences, Janssen Research & Development, LLC
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Scalability of Planova™ BioEX Filters
Daniel Strauss, Senior Scientist, Science and Technology, Asahi Kasei Bioprocess America, Inc.
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Filtration Study to Remove Mycoplasma Acholeplasma laidlawii with Planova™ 20N and BioEX Filters
Masayasu Takahara, Manager, Technical Marketing, Bioprocess, Asahi Kasei Medical Co., Ltd.
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Fine Tuning Viral Clearance Approaches with a Total Viral Load Strategy
Michael Burnham, Director, Purification and Process Development, WuXi AppTec, Inc.
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Effects of Pressure and Process Pausing on Viral Removal During Viral Filtration
Sean O'Donnell, Senior Research Scientist, Virology and Purification Development, Eli Lilly and Company
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Regulatory Update on Virus Safety of Biological Products
Johannes Blümel, Head of Virus Safety Section, Virology, Paul-Ehrlich-Institut
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Pressure and Flow Variations, Filter Integrity Testing: Robustness Questions Answered?
Thomas R. Kreil, Associate Professor of Virology, Senior Director, Global Pathogen Safety, Shire
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Asahi Gold Particle Test System (AGPTS) : Confidence in Automation
Michael Proctor, Manager, Zemaira Manufacturing, CSL Behring
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Planova™ 35N Nanofiltration of a Plasma-Derived Immune Globulin Product
Barry D. Gooch, Section Head of Pathogen Safety Development & Validation, R&D Bioscience Industrial Group, North Carolina R&D, Grifols, Inc.
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Effective and Robust Virus Filtration
Nathan J. Roth, Senior Director & Head Global Pathogen Safety, CSL Behring
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Robust Virus Filtration Processes: Protein Filterability and Viral Clearance
Tomoko Hongo-Hirasak, Manager, Technology Development, Bioprocess, Asahi Kasei Medical
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Evaluation of Virus Filtration Operation, Scale Up and Validation for a Fusion Protein
Dharmesh Kanani, Senior Scientist, Downstream Process Development & Operations, Global CMC Biologics, Teva Biopharmaceuticals
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Screening, Scale-Up and Validation of Virus Filtration for Aggregatable mAb Product
Dong-Woo Lee, Manager, Purification Process Team / R&D Center, Celltrion, Inc.
19th Planova™ workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Evaluation of Asahi Planova™ BioEX Viral Filter Used in Therapeutic Antibody Manufacturing Processes
Shengjiang Shawn Liu, Head and Chief Scientist, Pathogen Safety, Biological Development, Bayer HealthCare Pharmaceuticals
19th Planova™ Workshop
Sep 22, 2016 to Sep 23, 2016
Philadelphia -
Pathogen Safety Concepts for Biotechnology: from Plasma Products, to Recombinant Proteins, to Advanced Therapy Medicinal Products
Thomas R. Kreil, Associate Professor of Virology Senior Director Global Pathogen Safety, Shire
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Defining the Design Spaces for Robust Viral Clearance in Planova™ 20N and BioEX Processes
Daniel Strauss, Senior Scientist Science and Technology, Asahi Kasei Bioprocess America, Inc.
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Virus Retentive Filtration 2017- Regulatory Expectations and Challenges
Horst Ruppach, Global Director Viral Clearance and Virology Charles River, Biologics Testing Solutions
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
A General Mechanistic Model for Viral Filtration
Anupam Shukla, Associate Professor Department of Chemical Engineering, Indian Institute of Technology Delhi
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Indian Perspective : Plasma Derived Medicinal Products
Ranjeet S. Ajmani, Chief Executive Officer, PlasmaGen BioSciences Pvt Ltd.
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Current Technologies for Human Plasma-Derived Products
Thierry Burnouf, Director and Professor, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Manufacturing Biopharmaceuticals and Biologicals: Current Trends, Challenges and Technology Drivers
Sandeep B. Kale, Deputy Coordinator of DBT-ICT-Centre for Energy Biosciences Associate Professor & Co-ordinator for M. Tech. Program, Institute of Chemical Technology
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Development of Planova™ 20N Filtration for a Higher Concentration mAb: A Case Study
Suhas Rajeeva, Purification Team Lead and Associate Scientific Manager, Biocon Research Limited
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Implementing Nano Filtration for Platform Manufacturing of Monoclonal Antibodies
Girish M. Masand, Deputy General Manager, Therapeutic Proteins - Process Development, Reliance Life Sciences Pvt Ltd.
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
From Lab to Production Scale: Challenges and Implementation of Virus Removal Filters in Large-scale GMP-manufacturing
Christian Koch, Senior Transfer Engineer, Product Transfer & Process Engineering - Protein Purification, Boehringer lngelheim Pharma GmbH & Co. KG
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Screening, Scale-Up and Validation of Virus Filtration for Aggregatable mAb Product
Dong-Woo Lee, Manager, Purification Process Team / R&D Center, Celltrion, Inc.
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Update on European Viral Safety Regulations
Johannes Blümel, Head of Virus Safety Section Department of Virology, Paul-Ehrlich-Institut
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
A Review of Virus Filter Performance ‒ Critical Process Parameters and Best Practice
Horst Ruppach, Global Director, Viral Clearance and Virology, Charles River
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Differential Retention of Parvoviruses During Virus Filtration
Thomas Nowak, Senior Manager, Virus Safety Development R&D, CSL Behring
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Introduction of a Nanofiltration Step in FVIII Purification Process
Filippo Mori, Senior Researcher, Research Department, Kedrion
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Aspects Impacting Virus Filter Selection for Cell Culture-Based Biomanufacturing Processes
Sven Schubert, Senior Process Manager, DSP Process Design / Validation, Rentschler Biopharma SE
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Impact of Prefilter and Operating Parameters on Virus Filter Performance
Sean O'Donnell, Principal Research Scientist, Virology and Purification Development, Eli Lilly and Company
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Evaluation of Pre-Filtration on BioEX Process Performance for Monoclonal Antibodies
Ashlee Smith, Associate Scientist, API-Large Molecule, Janssen Research and Development
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Viral Filtration of a Therapeutic Monoclonal Antibody: Impact of Clarification Impurities
Hendri Tjandra, Senior Staff Scientist, Drug Discovery - Biologics Development, Bayer
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Validation of Planova™ 20N as an Alternative Virus Reduction Filter for a Commercial Product
Denis P. Twomey, Principal Scientist Pharmaceutical Development and Manufacturing Sciences, Janssen Sciences Ireland UC
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Downscaling a Manufacturing Process with Planova™ 20N Filters for Viral Clearance Study
Javier Castrillo, Downstream Technician / Downstream Scientist, Process Development, mAbxience
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
High Capacity Filtration: Biotest Next Level, a New Plant to Manufacture a Human Immunoglobulin G Preparation with Removal of Viruses by a Planova™ BioEX Filtration
Marcel Asper / Michael Rodemer, Director, Virus Laboratory, Pathogen Safety / Director, Project Manager, BNL,Biotest
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Upstream Virus Barriers: Why and How
Andreas Wieser, Senior Laboratory Associate Global Pathogen Safety, Shire
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Challenges of Implementing Virus Filtration into Continuous Manufacturing
Daniel Strauss, Principal Scientist, R&D, Asahi Kasei Bioprocess America
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Planova™ History in Technological Innovation Recognized in Virus Removal Filter
Seiichi Manabe, Head of a Technical Adviser Office, Manabe Gijutsushi Jimusho
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Process evaluation and search for devices for prion removal using mouse adapted vCJD
Oscar Jun Adan-Kubo, Research Scientist, Infectious Pathogen Research Group, R&D, Benesis Corporation
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Experience with Reduction of Small Non-enveloped Viruses
Johannes Blümel, Head of virus safety section, Paul Ehrlich Institute
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Understanding Planova™ Virus Filtration and Designing Robust Virus Filtration Processes
Tomoko Hongo-Hirasaki, Senior Scientist, Group Manager of Evaluation and Analysis, Asahi Kasei Medical
20th Planova™ Workshop
Nov 9, 2017 to Nov 10, 2017
Prague -
Process Development for High Concentration Mab with Planova™ BioEX Filter
Roy Kahn, Researcher, DSP Process Development, InSight Biopharmaceuticals Ltd.
2nd Planova™ Workshop in India
Feb 9, 2017
Goa -
Process Development for High Concentration Mab with Planova™ BioEX Filter
Roy Kahn, Ph.D, Researcher, DSP, Process Development, InSight Biopharmaceuticals Ltd.
19th Planova™ Workshop
Sep 22, 2016
Philadelphia -
Design of Experiment (DoE) Applied to the Optimization of the Filtration of FVIII on a 20-20 nm Planova™ Filters Sequence. Demonstration of the Step Robustness and Implementation into the LFB FVIII Manufacturing Process
Michel POULLE, Head of Process Laboratory, Industrial Support Unit, Department of Industrial Processes, LFB Biomedicaments
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Process Development for High Concentration Mab with Planova™ BioEX Filter
Roy KAHN, Researcher, DSP, Process Development, InSight Biopharmaceuticals Ltd
18th Planova™ Wokshop
Oct 22, 2015 to Oct 23, 2015
Athens -
Implementation of the Planova™ Virus Reduction Filter into an Established Manufacturing Process
Andrew Griffiths, Scientist, Process Support, Biosciences, Emergent BioSolutions
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Regulatory Update on Virus Safety with a Focus on Nanofiltration
Johannes Blümel, Head of Virus Safety Section, Virology, Paul-Ehrlich-Institut
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Clarification of Cell Culture Supernatant Using BioOptimal™ MF-SL Modules in Early-Stage R&D
Yuichiro Shimizu,Researcher,ChugaiPharmabody Research
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Combining Planova™ Filters in Series Provides a Synergistic Enhancement of Viral Clearance Capability While Mitigating Process Risks
Daniel Strauss, Senior Scientist, Science and Technology, AsahiKasei Bioprocess
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Process Development and Scale-Up of MABp1 Using Planova™ 20N and QyuSpeedTM D
Josh Combs,Vice President, Manufacturing,XBiotech
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
VRF: The UCB Experience
Nicola Humpherson,Principal Scientist, Downstream Process Sciences,UCB
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Planova™ 35N Nanofiltration of a Plasma-Derived Immune Globulin Product
BarryGooch, Senior Research Scientist II, R&D, Pathogen Safety,Grifols
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Interruption of Filtration and Residual Virus in the Filtrate
Herbert Dichtelmüller, President, ViruSafe-Consult
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Process Designing for Virus Removal Filtration
Tomoko Hongo-Hirasaki,Manager, Bioprocess Technology Development Department,Asahi Kasei Medical
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Virus Filter Breakthrough Modes and Risk Mitigation Strategies
Kurt Brorson, Scientist, CDER, FDA
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Virus Removal is Affected by Flux, Brownian Motion of Virus and Virus-Membrane Interaction
Oscar Jun Adan-Kubo, Lead Researcher, Protein Pharmacology Research Section, Japan Blood Products Organization
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
Determination of Viral Clearance Design Spaces on Planova™ 20N and BioEX Filters
Josh Goldstein, Scientist, Pharmaceutical Development and Manufacturing Sciences, Janssen Research & Development
17th Planova™ Workshop
Jun 12, 2014 to Jun 13, 2014
Washington, D.C. -
New Planova™ Oita Plant for Secure Global Supply Chain
Shuji Fujita, Manager,Asahi Kasei Medical Co., Ltd.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Bispecific Antibody Purification and Virus Filtration Challenges
Germano Coppola,Associate Director, Process Sciences,Abbvie Bioresearch Centre Inc.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
The Application of Planova™ BioEX in the Plasma-Derived IVIG Manufacturing Process
Yang HuHu, Engineer, Shandong Taibang Biological Products, Co., Ltd.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Structure of Filter Membrane and Brownian Motion of Virus Affects Virus Removal
Oscar Jun Adan-Kubo, Lead Researcher, Japan Blood Products Organization
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Introduction of Automated Planova™ Filtration Systems at Janssen Biologics B.V.
Guido Ragetlie, Principal Engineer, Janssen Biologics B.V.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Robust Strategy Development for Primary Recovery of High Cell Density Mammalian Cell Cultures Using Ultra Scale-Down Models
Daria Popova, Research Engineer, Department of Biochemical Engineering, University College London
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Panel Disucussion: Parvovirus Retentive Properties of Planova™ Filters under Various Conditions - Process Interruption and Pressure Level -
Dr. Herbert Dichtelmueller with Dr. Bluemel, Dr. Kreil, Mr. Nothelfer, Dr. Hongo, Mr. Sato, Dr. Ruppach, Dr.Bailey
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Characteristics and Optimum Selection of Planova™ Virus Removal Filters
Tomoko Hongo-Hirasaki, Manager, Asahi Kasei Medical Co., Ltd.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Virus Filtration and Biotechnology Processes
Thomas Kreil,Associate Professor of Virology, Senior Director Global Pathogen Safety, Baxter BioScience
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Large Volume Filtration with Novel Virus Preparation Method
Kazuya Kobayashi, R&D Staff, Asahi Kasei Medical Co., Ltd.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Investigations of PCV Removal by Planova™ Filters Smaller than 15 nm
Andy Bailey, CEO and Operations Director, ViruSure GmbH
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
lmprovements in Down-scaling of Virus Filtration
Andreas Wieser,Senior Laboratory Associate,Global Pathogen Safety, Baxter BioScience
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Process Improvement, Virus Removal Data and Regulatory Background for Changing a Nanofilter of F-IX Product.
Regina Voges-Haas, Head of Laboratory Development Plasma Proteins, Biotest AG
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Application of Planova™ Virus Filters in Recombinant Protein and mAb Purification Processes - Process Performance and Viral Removal Data -
Franz Nothelfer, Associate Director, Protein Science, Boehringer Ingelheim Pharma GmbH & Co. KG
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Nanofiltration in Plasma-derived IVIG - Process Design for Full Scale Production
Alessandra Lazzarotti, Scientist, Industrial Development & Research, Kedrion Biopharma S.p.A.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome -
Process Development and Scale-up of Planova™ 20N Filters
Solomon Alva, Scientific Manager, Research & Development, Biocon Limited
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Development of Viral Filtration Process for Monoclonal Antibody
Lalit Saxena, Manager, Production, Mabpharm Private Limited
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Asahi Product Development Concept
Terry Sato/Hironobu Shirataki, General Manager/Global Product Manager, Asahi Kasei Medical Co., Ltd.
1st Planova™ Workshop in India
Jan 31, 2013
Goa -
Parameters Impacting Pathogen Removal Capacity of Virus Filters - General Considerations
Albrecht Gröner, Head Pathogen Safety, CSL Behring
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Implementation of Automatic Cleaning and Integrity Testing of Planova™ Filters
J.F. van de Laar, Plasma Products, Dept. of Process Support and Development, Sanquin
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Development of a Viral Filtration Step
Erich Blatter, Senior Scientist, Purification Sciences Human Genome Sciences, Inc.
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Scale-Up of Planova™ 20N Filtration for Commercial Production of Monoclonal Antibodies Using a Platform Approach
Tom Belval, Principal Engineer, Global Process Engineering, Amgen
15th Planova™ Workshop
Jun 14, 2012 to Jun 15, 2012
Boston -
Implementation of Automatic Cleaning and Integrity Testing of Planova™ Filters at Sanquin Plasma Products
J.F. van de Laar, Plasma Products, Dept. of Process Support and Development, Sanquin
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Use of In-house Platform Data to Support Reduced Viral Clearance Validation
Stefan Hepbildikler, Director, Recovery & Downstream Processing C, Roche Pharma Biotech Development
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Process Designing for Virus Removal Filter
Tomoko Hongo-Hirasaki, Manager, Technology Development Department, Asahi Kasei Medical Co., Ltd.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Comparison of Downscale and Process Virus Retentive Filter
Marcel Asper, Study Director, Charles River Biopharmaceutical Services GmbH
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Selection of a Virus Filter for a Plasma Product
Shirley Stagg, Senior Project Scientist, Biosafety and Product Development, Bio Products Laboratory Ltd.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
The Goal of Increasing Safety in Different Plasma Derivative Manufacturing Processes: 15 Years Experience of Grifols with Planova™ Nanofiltration
Santiago Caballero, Santiago Caballero, Ph.D., Instituto Grifols, S.A.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne -
Removal Capacity of Transmissible Spongiform Encephalopathy (TSE) Model Agents in Plasma Products. Nanofiltration Contribution.
Francisco J. Belda, Head Virology Section, Instituto Grifols S.A.
16th Planova™ Workshop
Nov 7, 2013 to Nov 8, 2013
Rome